Divalproex Sodium Capsule, Delayed Release
Product Images NDC 46708-821

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 46708-821). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex-125mg (Divalproex 125mg)

Each capsule contains divalproex sodium, USP equivalent to 125 mg of valproic acid. Store at 25°C (77°F) with excursions permitted at 15° to 30°C (59° to 86°F). Ensure the seal over the the bottle opening is intact before use. The capsule can be taken whole or opened and the contents put on food for administration. This medication is packaged in a child-resistant container. The manufacturer is Alembic Pharmaceuticals Limited in India. NDC 46708-821-31. Dispense with the Medication Guide.*

FDA Label Image

Divalproex-figr1.jpg (Divalproex Figr1)

This text shows a graph displaying the percentage reduction in CPS (Child-Pugh Score) rate for patients taking Divalproex Sodium compared to Placebo. It includes percentages ranging from -100% to 100% and indicates the % of patients showing improvement, no change, or worsening in their condition.*

FDA Label Image

Divalproex-figr2.jpg (Divalproex Figr2)

FDA Label Image

Divalproex-ifu-p2.jpg (Divalproex Ifu P2)

FDA Label Image

Divalproex-ifu-p3.jpg (Divalproex Ifu P3)

FDA Label Image

Divalproex-ifu-p4.jpg (Divalproex Ifu P4)

FDA Label Image

Divalproex-ifu-p5.jpg (Divalproex Ifu P5)

FDA Label Image

Divalproex-structure.jpg (Divalproex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.